12:00 AM
 | 
Jul 23, 2012
 |  BC Week In Review  |  Company News  |  Other News

Actelion infectious, inflammation, cardiovascular news

At June 30, the company had CHF1.4 billion ($1.5 billion) in cash including CHF378.9 ($396.4 million) in restricted cash and a six-month operating gain of CHF229.2 million ($239.8 million). The company spent CHF232.1 million ($242.8 million) on R&D in the first half of 2012.

Earlier this month, Actelion said it will cut up to 135 positions, or about 5%...

Read the full 278 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >